Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE: Hygiene Measures to Prevent MRSA Infection
NCT02572791Phase 4Completed
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2015
- Primary completion
- Nov 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mupirocin and chlorhexidine in Staphylococcus aureus infection and skin and soft tissue infection (SSTI) (3 arms), sponsored by Washington University School of Medicine. Primary endpoint: Number of Households With at Least One Skin and Soft Tissue Infection at 3 months. Started Oct 2015; status: completed.
02
Drugs
mupirocinchlorhexidine
03
Conditions
Staphylococcus aureus infectionskin and soft tissue infection (SSTI)
Beyond the preview
Go deeper on NCT02572791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02572791.